title: Telomerase assay as a possible predictor of the response to anticancer chemotherapy.
abstract: BACKGROUND
  The correlation between telomerase activity and antitumor effects was investigated in cell lines of human gastric (MKN-28, MKN-45, and MKN-74) and breast (T-47D, MCF-7, ZR75-1) cancers to evaluate the possibility of utilizing this enzyme to predict tumor response to chemotherapy.
  
  
  METHODS
  After culture with various concentrations of 5-fluorouracil (5-FU) or doxorubicin (DOX) for 3 days, cell viability (trypan blue exclusion), cell cycle distribution (flow cytometry), and telomerase (TRAP-EZE) were measured.
  
  
  RESULTS
  Telomerase activity correlated significantly with the number of viable cells. After drug exposure, this activity decreased rapidly in a dose-dependent fashion in most cell lines. There was no correlation between telomerase activity and the distribution of cells in the cell cycle.
  
  
  CONCLUSIONS
  As the assay for telomerase activity is extremely sensitive and is virtually specific to cancer cells, this method may prove useful for the sensitivity testing of small specimens of human tumors.
authors.affiliation: Department of Surgery, Iwate Medical University, Morioka, Japan. mterashi@iwate-med.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Terashima
authors.forename: I
authors.initials: I
authors.lastname: Takiyama
authors.forename: N
authors.initials: N
authors.lastname: Uesugi
authors.forename: N
authors.initials: N
authors.lastname: Sasaki
authors.forename: A
authors.initials: A
authors.lastname: Takagane
authors.forename: Y
authors.initials: Y
authors.lastname: Hayakawa
authors.forename: K
authors.initials: K
authors.lastname: Abe
authors.forename: M
authors.initials: M
authors.lastname: Araya
authors.forename: S
authors.initials: S
authors.lastname: Nishizuka
authors.forename: O
authors.initials: O
authors.lastname: Shimooki
authors.forename: T
authors.initials: T
authors.lastname: Nakaya
authors.forename: T
authors.initials: T
authors.lastname: Irinoda
authors.forename: H
authors.initials: H
authors.lastname: Yonezawa
authors.forename: K
authors.initials: K
authors.lastname: Oyama
authors.forename: K
authors.initials: K
authors.lastname: Saito
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000473:pathology; D004317:Doxorubicin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D005260:Female; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D009363:Neoplasm Proteins / Q000032:analysis*; D013274:Stomach Neoplasms / Q000473:pathology; D019098:Telomerase / Q000032:analysis*; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D004317:Doxorubicin; D019098:Telomerase; D005472:Fluorouracil